Inotek Pharmaceuticals Corporation (ITEK) Shares are Down -1.32%

Inotek Pharmaceuticals Corporation (ITEK) : During the past 4 weeks, traders have been relatively bearish on Inotek Pharmaceuticals Corporation (ITEK), hence the stock is down -28.65% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.66% relative to the S&P 500. The 4-week change in the price of the stock is -28.8% and the stock has fallen -1.32% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 3.02% and the fifty day Moving Average is 12.08%. Inotek Pharmaceuticals Corporation has dropped 25% during the last three month period . Year-to-Date the stock performance stands at -40.42%.

Inotek Pharmaceuticals Corporation (ITEK) : The most positive equity analysts on Inotek Pharmaceuticals Corporation (ITEK) expects the shares to touch $40, whereas, the least positive believes that the stock will trade at $24 in the short term. The company is covered by 2 Wall Street Brokerage Firms. The average price target for shares are $32 with an expected fluctuation of $11.31 from the mean.


Inotek Pharmaceuticals Corporation (NASDAQ:ITEK): On Fridays trading session , Opening price of the stock was $6.56 with an intraday high of $6.95. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $6.56. However, the stock managed to close at $6.75, a loss of 0.44% for the day. On the previous day, the stock had closed at $6.78. The total traded volume of the day was 107,896 shares.

Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company advancing molecules with new mechanisms of action to address diseases of the eye. The Companys business strategy is to develop and progress its product candidates through human clinical trials. The Company is focused on the discovery, development and commercialization of therapies for glaucoma. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that is designed to lower intraocular pressure (IOP) by restoring the eyes natural pressure control mechanism. The Companys product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.